-

Global Mesenchymal Stem Cells Market Intelligence Report 2022: Featuring Key Players Merck, Genlantis, Cell Applications & Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Mesenchymal Stem Cells Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The Global Mesenchymal Stem Cells Market is projected to reach USD 5,847.88 million by 2027 from USD 2,731.51 million in 2021, at a CAGR 13.52% during the forecast period.

Market Statistics:

  • The Americas Mesenchymal Stem Cells Market size was estimated at USD 1,113.77 million in 2021 and expected to reach USD 1,244.58 million in 2022, at a CAGR 12.99% to reach USD 2,317.98 million by 2027.
  • The Asia-Pacific Mesenchymal Stem Cells Market size was estimated at USD 667.85 million in 2021 and expected to reach USD 780.85 million in 2022, at a CAGR 14.67% to reach USD 1,518.45 million by 2027.
  • The Europe, Middle East & Africa Mesenchymal Stem Cells Market size was estimated at USD 949.88 million in 2021 and expected to reach USD 1,070.73 million in 2022, at a CAGR 13.31% to reach USD 2,011.44 million by 2027.

Market Segmentation & Coverage

Type:

  • Allogeneic
  • Autologous

Indication:

  • Bone & Cartilage Repair
  • Cancer
  • Cardiovascular Disease
  • GvHD
  • Inflammatory & Immunological Disease
  • Liver Diseases

Source of Isolation:

  • Adipose Tissues
  • Bone Marrow
  • Cord Blood
  • Fallopian Tube
  • Fetal Liver
  • Lung
  • Peripheral Blood

Application:

  • Disease Modeling
  • Drug Development & Discovery
  • Stem Cell Banking
  • Tissue Engineering
  • Toxicology Studies

Region:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
  • Europe, Middle East & Africa
    • France
    • Germany
    • Italy
    • Netherlands
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • United Arab Emirates
    • United Kingdom

Company Usability Profiles:

  • Astellas Pharma Inc.
  • Axol Biosciences Ltd.
  • BrainStorm Cell Therapeutics Inc.
  • Cell Applications, Inc.
  • Celprogen, Inc.
  • Cyagen Biosciences, Inc.
  • Genlantis, Inc.
  • Lonza Group AG
  • Merck KGaA
  • Mesoblast Limited
  • Neuromics
  • Pluristem Therapeutics Inc.
  • PromoCell GmbH
  • R&D Systems, Inc.
  • ScienCell Research Laboratories, Inc.
  • Smith & Nephew PLC
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • Vericel Corporation

Key Topics Covered:

1. Preface

2. Research Methodology

3. Market Overview

4. Americas Mesenchymal Stem Cells Market

5. Asia-Pacific Mesenchymal Stem Cells Market

6. Europe, Middle East & Africa Mesenchymal Stem Cells Market

7. Company Usability Profiles

For more information about this report visit https://www.researchandmarkets.com/r/j2hcuq

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Protein Engineering for Pharmaceutical Biotechnology Training Course: Understand How to Advance Therapeutic Development and Industrial Applications (Jan 21st - Jan 22nd, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Protein Engineering for Pharmaceutical Biotechnology Training Course (Jan 21st - Jan 22nd, 2026)" training has been added to ResearchAndMarkets.com's offering. Enhance your knowledge in protein engineering to understand how to advance therapeutic development and industrial applications. Protein-based therapeutics have significantly advanced and created new paradigms in disease treatment. Half of the top ten selling drugs in 2023 were protein-based therapeutics. Pro...

Development of Combination Products: 2 Day Critical Interactions Training Course (Feb 9th - Feb 10th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Development of Combination Products: Critical Interactions Training Course (Feb 9th - Feb 10th, 2026)" training has been added to ResearchAndMarkets.com's offering. The programme will cover the regulatory strategy to adopt and the relevant aspects of GMP and quality processes, including the data expectations for the CTD. It will also review the key relationships between quality, regulatory, R&D and production. Delegates will find this a comprehensive overview o...

Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course (Feb 11th - Feb 12th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course (Feb 11th - Feb 12th, 2026)" training has been added to ResearchAndMarkets.com's offering. This two-day workshop has been designed specifically for product developers who want to incorporate human factors testing into their product development or need to provide the regulators with specific usability data for their device to comply with the MDR. The format for the d...
Back to Newsroom